Fujimoto-Ouchi K - Search Results

1

Sequential treatment with irinotecan and doxifluridine: optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer.

Mishima H, Kato T, Yanagisawa M, Tsujinaka T, Nishisho I, Tsujie M, Fujimoto-Ouchi K, Tanaka Y, Kikkawa N. Mishima H, et al. Chemotherapy. 2005 Mar;51(1):32-9. doi: 10.1159/000084416. Epub 2005 Mar 14. Chemotherapy. 2005. PMID: 15767743 Clinical Trial.

2

Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models.

Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Fujimoto-Ouchi K, et al. Cancer Chemother Pharmacol. 2002 Mar;49(3):211-6. doi: 10.1007/s00280-001-0401-7. Epub 2001 Dec 22. Cancer Chemother Pharmacol. 2002. PMID: 11935213

3

Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.

Fujimoto-Ouchi K, Onuma E, Shirane M, Mori K, Tanaka Y. Fujimoto-Ouchi K, et al. Cancer Chemother Pharmacol. 2007 May;59(6):807-15. doi: 10.1007/s00280-006-0338-y. Epub 2006 Sep 29. Cancer Chemother Pharmacol. 2007. PMID: 17009035

4

Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.

Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. Fujimoto-Ouchi K, et al. Cancer Chemother Pharmacol. 2007 May;59(6):795-805. doi: 10.1007/s00280-006-0337-z. Epub 2006 Oct 10. Cancer Chemother Pharmacol. 2007. PMID: 17031648

5

Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.

Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Fujimoto-Ouchi K, et al. Clin Cancer Res. 2001 Apr;7(4):1079-86. Clin Cancer Res. 2001. PMID: 11309360

6

Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.

Yanagisawa M, Fujimoto-Ouchi K, Yorozu K, Yamashita Y, Mori K. Yanagisawa M, et al. Oncol Rep. 2009 Aug;22(2):241-7. Oncol Rep. 2009. PMID: 19578762

7

Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.

Hiraga T, Hata K, Ikeda F, Kitagaki J, Fujimoto-Ouchi K, Tanaka Y, Yoneda T. Hiraga T, et al. Oncol Rep. 2005 Sep;14(3):695-9. Oncol Rep. 2005. PMID: 16077977

8

[Efficacy of combination chemotherapy of cyclophosphamide and 5'-deoxy-5-fluorouridine in a mammary tumor xenograft model, MX-1].

Endo M, Fujimoto-Ouchi K, Matsumoto T, Tanaka Y, Ishitsuka H. Endo M, et al. Gan To Kagaku Ryoho. 1997 Aug;24(10):1295-301. Gan To Kagaku Ryoho. 1997. PMID: 9279349 Japanese.

9

[Antitumor activity of various cytostatics in mice bearing murine advanced tumors].

Fujimoto-Ouchi K, Tamura S, Mori K, Ishikawa T, Eda H, Tanaka Y, Ninomiya Y, Ishitsuka H. Fujimoto-Ouchi K, et al. Gan To Kagaku Ryoho. 1993 Dec;20(15):2361-7. Gan To Kagaku Ryoho. 1993. PMID: 8259852 Japanese.

10

Biomarkers for antitumor activity of bevacizumab in gastric cancer models.

Yamashita-Kashima Y, Fujimoto-Ouchi K, Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H, Mori K. Yamashita-Kashima Y, et al. Among authors: fujimoto ouchi k. BMC Cancer. 2012 Jan 25;12:37. doi: 10.1186/1471-2407-12-37. BMC Cancer. 2012. PMID: 22273502 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters